Yes. I don't know if the post from geffa9 was directed to me, but people love to cherry pick posts and only highlight a section of something, no amount of clarifications seem to matter!
Milestones are earnings. We pay tax on them. The cash goes to our balance sheet. They matter, particularly when there are so many to potentially be paid in future.
Although I agree that PE (whether forward or trailing) is a bad metric to value Neuren, Forward estimates is simply a function of reoccurring revenue (times a multiplier) + the one offs expected for that period (without a multiplier). The facts are that we're expecting a large profit for the second year in a row. We know our costs are roughly 20m for the first half (which is mostly R&D), hence the forward PE estimate for 2024 that I posted.
What happens in 2025, 2026, 2027 depends on the timing on milestones and the expansion of Daybue in RoW - I also doubt we'll be around by then anyway.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$14.20 |
Change
0.890(6.69%) |
Mkt cap ! $1.761B | |||
| Open | High | Low | Value | Volume |
| $13.50 | $14.26 | $12.96 | $9.111M | 655.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2000 | $14.17 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.23 | 3278 | 1 |
View Market Depth
| Last trade - 16.15pm 27/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |